Business Context and Reporting Period
This Form 8-K Current Report was filed by Vanda Pharmaceuticals Inc. on May 6, 2016. The filing discloses the entry into a Material Definitive Agreement with Patheon Inc. regarding the commercial manufacturing of Vanda's product, Fanapt (iloperidone).
Key Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the terms of a new contractual agreement rather than financial performance results.
Material Changes and Agreement Details
On May 6, 2016, Vanda entered into a Manufacturing Agreement with Patheon Inc. for the production of commercial supplies of Fanapt tablets (1 mg through 12 mg) at Patheon's Mississauga, Ontario, Canada site.
- Scope: Vanda supplies the active pharmaceutical ingredient; Patheon handles manufacturing, quality control, and packaging.
- Commitment: Vanda agreed to order at least 70% of its total yearly requirement of new Fanapt units for the U.S. and specified countries.
- Term: The initial term is five years, with automatic renewal for successive one-year terms unless terminated with 12 months' notice.
- Termination: Vanda may terminate for regulatory reasons (30 days' notice), discontinuation of development (6 months' notice), or for any reason after three years (12 months' notice, subject to liquidated damages). Either party may terminate for material breach, insolvency, or force majeure.
- Exit Obligations: Upon expiration or termination, Vanda must purchase undelivered ordered quantities and Patheon's work-in-process inventory.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or management commentary on future earnings. The primary risk disclosed relates to the binding nature of the agreement, including the obligation to purchase inventory upon termination and the potential for liquidated damages if Vanda terminates early for convenience. The full text of the agreement is referenced as an exhibit to the upcoming Form 10-Q for the quarter ending June 30, 2016.
Investor Verification Checklist
- Verify the total projected cost of the 70% supply commitment against current cash reserves.
- Review the specific liquidated damages formula in the full agreement text (to be filed in the Q2 2016 10-Q).
- Assess the impact of the 70% minimum order requirement on inventory levels if sales forecasts decline.
- Confirm the creditworthiness of Patheon Inc. as a manufacturing partner.